BRIEF published on 03/24/2026 at 07:35, 1 month 13 days ago Sanofi's Q1 2026 financial guide is now online Investors Quarterly Results Sanofi Financial Document Q1 2026
BRIEF published on 03/24/2026 at 07:35, 1 month 13 days ago Sanofi publie un aide-mémoire du premier trimestre 2026 pour soutenir l'analyse financière Innovation Biopharma Sanofi Modélisation Financière Résultats Du T1 2026
BRIEF published on 03/24/2026 at 07:35, 1 month 13 days ago Mise en ligne du guide financier Q1 2026 de Sanofi Investisseurs Résultats Trimestriels Sanofi Document Financier Q1 2026
BRIEF published on 03/24/2026 at 07:35, 1 month 13 days ago Sanofi Releases Q1 2026 Aide-Mémoire to Support Financial Analysis Innovation Biopharma Sanofi Financial Modeling Q1 2026 Results
PRESS RELEASE published on 03/24/2026 at 07:30, 1 month 13 days ago Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire » Mise en ligne du document 'Q1 2026 aide-mémoire' par Sanofi pour faciliter la modélisation financière des résultats trimestriels avec des déclarations prospectives Déclarations Prospectives Sanofi Modélisation Financière Aide-mémoire Q1 2026
PRESS RELEASE published on 03/24/2026 at 07:30, 1 month 13 days ago Press release: Availability of the Q1 2026 aide-mémoire Sanofi announces availability of Q1 2026 aide-mémoire for financial modelling purposes. Details on non-comparable items, currency impact, and share count included. Results to be published on April 23, 2026 Sanofi Results Aide-mémoire Financial Modelling Q1 2026
BRIEF published on 03/18/2026 at 07:05, 1 month 19 days ago Sanofi: Breakthrough Therapy Designation for venglustat in the United States FDA Sanofi Venglustat Medical Discovery Gaucher's Disease
BRIEF published on 03/18/2026 at 07:05, 1 month 19 days ago Sanofi's Venglustat Earns Breakthrough Therapy Designation for Gaucher Disease Type 3 FDA Sanofi Breakthrough Therapy Venglustat Gaucher Disease
BRIEF published on 03/18/2026 at 07:05, 1 month 19 days ago Le venglustat de Sanofi obtient la désignation de thérapie innovante pour la maladie de Gaucher de type 3 FDA Sanofi Thérapie Révolutionnaire Venglustat Maladie De Gaucher
BRIEF published on 03/18/2026 at 07:05, 1 month 19 days ago Sanofi : Désignation de thérapie innovante pour le venglustat aux États-Unis FDA Sanofi Venglustat Maladie De Gaucher Découverte Médicale
Published on 05/07/2026 at 05:40, 37 minutes ago New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 4 hours 17 minutes ago Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 6 hours 47 minutes ago Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 7 hours 12 minutes ago Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 7 hours 17 minutes ago Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance
Published on 05/07/2026 at 04:00, 2 hours 17 minutes ago L’Université chinoise de Hong Kong (CUHK) se classe en tête à Hong Kong et en Asie dans le dernier classement mondial des universités par discipline publié par QS (Quacquarelli Symonds)
Published on 05/07/2026 at 04:00, 2 hours 17 minutes ago CUHK Claims Top Positions in Hong Kong and Asia in the Latest QS World University Rankings by Subject
Published on 05/07/2026 at 03:50, 2 hours 27 minutes ago 450 MHz LTE: Stronger, Smarter Grid for Brazil
Published on 05/07/2026 at 00:47, 5 hours 30 minutes ago Blue Cap AG expands portfolio through the acquisition of Janoschka AG
Published on 05/07/2026 at 00:43, 5 hours 33 minutes ago EQS-Adhoc: Blue Cap AG Acquires Janoschka AG and Adjusts Forecast Due to Transaction
Published on 05/06/2026 at 18:00, 12 hours 17 minutes ago Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 12 hours 17 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 12 hours 17 minutes ago Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
Published on 05/06/2026 at 18:00, 12 hours 17 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2026
Published on 05/06/2026 at 17:45, 12 hours 32 minutes ago Information concerning the total number of voting rights and shares 2026 04 30
